123 related articles for article (PubMed ID: 27299192)
1. Retrospective Analysis of Atypical Glands Suspicious for Carcinoma in Transurethral Resection of Prostate.
Chen S; Patil PA; Lepe M; Lombardo KA; Amin A; Matoso A
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):186-191. PubMed ID: 27299192
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
[TBL] [Abstract][Full Text] [Related]
4. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion.
Herawi M; Parwani AV; Irie J; Epstein JI
Am J Surg Pathol; 2005 Jul; 29(7):874-80. PubMed ID: 15958851
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of prostate cancers detected after an initial diagnosis of 'atypical glands suspicious for cancer'.
Zhou M; Magi-Galluzzi C
Pathology; 2010 Jun; 42(4):334-8. PubMed ID: 20438405
[TBL] [Abstract][Full Text] [Related]
6. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.
Wojno KJ; Epstein JI
Am J Surg Pathol; 1995 Mar; 19(3):251-60. PubMed ID: 7532918
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.
Shah RB; Tadros Y; Brummell B; Zhou M
Hum Pathol; 2013 May; 44(5):786-94. PubMed ID: 23158212
[TBL] [Abstract][Full Text] [Related]
8. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of p63 and α-methyl acyl Co A racemase in resolving suspicious foci in prostatic needle biopsy and transurethral resection of prostate specimens.
Singh V; Manu V; Malik A; Dutta V; Mani NS; Patrikar S
J Cancer Res Ther; 2014; 10(3):686-92. PubMed ID: 25313761
[TBL] [Abstract][Full Text] [Related]
10. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
11. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
Wang W; Sun X; Epstein JI
Am J Surg Pathol; 2008 Jun; 32(6):851-7. PubMed ID: 18408595
[TBL] [Abstract][Full Text] [Related]
12. Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies.
Hosler GA; Epstein JI
Hum Pathol; 2005 May; 36(5):480-5. PubMed ID: 15948114
[TBL] [Abstract][Full Text] [Related]
13. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
14. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.
Epstein JI; Herawi M
J Urol; 2006 Mar; 175(3 Pt 1):820-34. PubMed ID: 16469560
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Epstein JI
Mod Pathol; 2004 Mar; 17(3):307-15. PubMed ID: 14739905
[TBL] [Abstract][Full Text] [Related]
16. Pseudohyperplastic prostatic adenocarcinoma in transurethral resections of the prostate.
Arista-Nasr J; Martinez-Benitez B; Valdes S; Hernández M; Bornstein-Quevedo L
Pathol Oncol Res; 2003; 9(4):232-5. PubMed ID: 14688829
[TBL] [Abstract][Full Text] [Related]
17. Adenosis of the prostate. Histologic features in needle biopsy specimens.
Gaudin PB; Epstein JI
Am J Surg Pathol; 1995 Jul; 19(7):737-47. PubMed ID: 7793471
[TBL] [Abstract][Full Text] [Related]
18. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
19. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
20. Adenosis of the prostate. Histologic features in transurethral resection specimens.
Gaudin PB; Epstein JI
Am J Surg Pathol; 1994 Sep; 18(9):863-70. PubMed ID: 7520673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
